NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.
View Top Employees from Light Chain Bioscience | Novimmune SAWebsite | http://www.lightchainbio.com |
Revenue | $23 million |
Funding | $182.6 million |
Employees | 84 (77 on RocketReach) |
Founded | 1998 |
Phone | +41 22 839 71 41 |
Fax | +41 22 839 71 42 |
Industry | Biotechnology Research, Business Services General, Drug Discovery, Next-generation antibody drug discovery, Business Services, Pharmaceuticals, Immunology, Bispecific antibody drugs, Clinical development |
Web Rank | 7 Million |
Keywords | Novimmune, Novimmune Suisse, Emapalumab, Ni-0101, Novimmuni Bispecific Antibodies |
Competitors | Avanir Pharmaceuticals, Celldex Therapeutics, Crystax Pharmaceuticals / Oryzon Genomics, MacroGenics, Inc., PharmAbcine Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies |
Looking for a particular Light Chain Bioscience | Novimmune SA employee's phone or email?
The Light Chain Bioscience | Novimmune SA annual revenue was $23 million in 2024.
Jack Barbut is the CEO of Light Chain Bioscience | Novimmune SA.
77 people are employed at Light Chain Bioscience | Novimmune SA.
The NAICS codes for Light Chain Bioscience | Novimmune SA are [541, 541714, 5417, 54171, 54].
The SIC codes for Light Chain Bioscience | Novimmune SA are [873, 87].